Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
Céline Louapre, Nicolas Collongues, Bruno Stankoff, et al.
JAMA Neurology (2020) Vol. 77, Iss. 9, pp. 1079-1079
Open Access | Times Cited: 440

Showing 1-25 of 440 citing articles:

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1990-2001
Open Access | Times Cited: 474
Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti, et al.
Annals of Neurology (2021) Vol. 89, Iss. 4, pp. 780-789
Open Access | Times Cited: 433
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
Amber Salter, Robert J. Fox, Scott D. Newsome, et al.
JAMA Neurology (2021) Vol. 78, Iss. 6, pp. 699-699
Open Access | Times Cited: 264
Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic
Maryam Sharifian, Philippe Huot, Michael Osherov, et al.
Journal of the Neurological Sciences (2020) Vol. 417, pp. 117085-117085
Open Access | Times Cited: 217
Impact of COVID-19 on people with physical disabilities: A rapid review
Audrey Lebrasseur, Noémie Fortin-Bédard, Josiane Lettre, et al.
Disability and health journal (2020) Vol. 14, Iss. 1, pp. 101014-101014
Open Access | Times Cited: 217
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
David Baker, C A K Roberts, Gareth Pryce, et al.
Clinical & Experimental Immunology (2020) Vol. 202, Iss. 2, pp. 149-161
Open Access | Times Cited: 194
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Renuka Raman, Krishna Patel, Kishu Ranjan
Biomolecules (2021) Vol. 11, Iss. 7, pp. 993-993
Open Access | Times Cited: 166
Multiple sclerosis
Dejan Jakimovski, Stefan Bittner, Robert Zivadinov, et al.
The Lancet (2023) Vol. 403, Iss. 10422, pp. 183-202
Closed Access | Times Cited: 164
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Ethan G. Brown, Lana M. Chahine, Samuel M. Goldman, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 4, pp. 1365-1377
Open Access | Times Cited: 155
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Steve Simpson, Edward De Brouwer, Tomáš Kalinčík, et al.
Neurology (2021) Vol. 97, Iss. 19
Open Access | Times Cited: 148
COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
Luigi Ferini‐Strambi, Maria Salsone
Journal of Neurology (2020) Vol. 268, Iss. 2, pp. 409-419
Open Access | Times Cited: 147
COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Barrier Relevance
Aneesha Achar, Chaitali Ghosh
Cells (2020) Vol. 9, Iss. 11, pp. 2360-2360
Open Access | Times Cited: 147
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 143
Long COVID: pathophysiological factors and abnormalities of coagulation
Simone Turner, Asad Khan, David Putrino, et al.
Trends in Endocrinology and Metabolism (2023) Vol. 34, Iss. 6, pp. 321-344
Open Access | Times Cited: 139
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder, Diego Centonze, Maria L. Naylor, et al.
CNS Drugs (2021) Vol. 35, Iss. 3, pp. 317-330
Open Access | Times Cited: 112
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
Maria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
Annals of Clinical and Translational Neurology (2021) Vol. 8, Iss. 8, pp. 1738-1744
Open Access | Times Cited: 103
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 63
Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression
Santenna Chenchula, Kota Vidyasagar, Saman Pathan, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 41
Obesity as an independent risk factor for COVID-19 severity and mortality
Borna Tadayon Najafabadi, Daniel Rayner, Kamyar Shokraee, et al.
Cochrane library (2023) Vol. 2023, Iss. 6
Open Access | Times Cited: 40
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
Ana Zabalza, Simón Cárdenas‐Robledo, Paula Tagliani, et al.
European Journal of Neurology (2020) Vol. 28, Iss. 10, pp. 3384-3395
Closed Access | Times Cited: 129
COVID-19 Among Patients With Multiple Sclerosis
Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Gajarzadeh, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 4
Open Access | Times Cited: 98
Hesitant or Not Hesitant? A Systematic Review on Global COVID-19 Vaccine Acceptance in Different Populations
Maria Giulia Salomoni, Zeno Di Valerio, Elisa Gabrielli, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 873-873
Open Access | Times Cited: 98
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Crystal Zheng, Indrani Kar, Claire Kaori Chen, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 879-896
Open Access | Times Cited: 92
Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis
Zixin Cai, Yan Yang, Jingjing Zhang
BMC Public Health (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 88
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis
Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 46, pp. 102472-102472
Open Access | Times Cited: 87
Page 1 - Next Page

Scroll to top